Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazole

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Nacev, Benjamin A ^a   Liu, Jun O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B; ATORVASTATIN; AURANOFIN; BROMOCRIPTINE; CHLORTETRACYCLINE; CLOMIFENE; CYCLOSPORIN A; DIGOXIN; DIIODOHYDROXYQUIN; ERGOSTEROL; ESTRADIOL; FELODIPINE; FLOXURIDINE; FLUINDOSTATIN; HYPERICIN; IDOXURIDINE; ITRACONAZOLE; MEVINOLIN; MICONAZOLE; MYCOPHENOLIC ACID; NIMODIPINE; PENTAMIDINE; PIMECROLIMUS; PROGESTERONE; RALOXIFENE; SERTRALINE; SIMVASTATIN; SUNITINIB; UNINDEXED DRUG; ANTIFUNGAL AGENT; COLLAGEN; CYCLOSPORIN; LAMININ; MATRIGEL; PROTEOGLYCAN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG COST; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENDOTHELIUM CELL; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; LEUKEMIA CELL LINE; MONOTHERAPY; NERVE SPROUTING; PREPUCE; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG COMBINATION; DRUG EFFECT; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; TIME; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTIFUNGAL AGENTS; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN; CYCLOSPORINE; DRUG COMBINATIONS; DRUG SYNERGISM; ENDOTHELIAL CELLS; FIBROBLASTS; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; ITRACONAZOLE; JURKAT CELLS; LAMININ; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 80053238983     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024793     Document Type: Article

References (37)

1. Carmeliet P, (2003) Angiogenesis in health and disease. Nat Med 9 (6): 653-660.
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (24): 2542-2550.
3. DiMasi JA, Hansen RW, Grabowski HG, (2003) The price of innovation: New estimates of drug development costs. J Health Econ 22 (2): 151-185.
4. Chong CR, Sullivan DJ Jr, (2007) New uses for old drugs. Nature 448 (7154): 645-646.
5. Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr, et al. (2007) Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2 (4): 263-270.
6. Chong CR, Qian DZ, Pan F, Wei Y, Pili R, et al. (2006) Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 49 (9): 2677-2680.
7. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, et al. (2008) Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 105 (50): 19579-19586.
8. Ren YR, Pan F, Parvez S, Fleig A, Chong CR, et al. (2008) Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One 3 (12): e4009.
9. Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, et al. (2010) Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst 102 (24): 1855-1873.
10. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panel. JAMA 300 (5): 555-570.
11. Cross MJ, Claesson-Welsh L, (2001) FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22 (4): 201-207.
12. Giavazzi R, Sennino B, Coltrini D, Garofalo A, Dossi R, et al. (2003) Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 162 (6): 1913-1926.
13. Kerbel RS, (2008) Tumor angiogenesis. N Engl J Med 358 (19): 2039-2049.
14. Laib AM, Bartol A, Alajati A, Korff T, Weber H, et al. (2009) Spheroid-based human endothelial cell microvessel formation in vivo. Nat Protoc 4 (8): 1202-1215.
15. Niemisto A, Dunmire V, Yli-Harja O, Zhang W, Shmulevich I, (2005) Robust quantification of in vitro angiogenesis through image analysis. IEEE Trans Med Imaging 24 (4): 549-553.
16. Korff T, Augustin HG, (1999) Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci 112 (Pt 19): 3249-3258.
17. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58 (3): 621-681.
18. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
19. Faivre S, Demetri G, Sargent W, Raymond E, (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6 (9): 734-745.
20. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (1): 327-337.
21. Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, et al. (2011) Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 30 (10): 1183-1193.
22. Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, et al. (2008) Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14 (1): 270-280.
23. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, et al. (2010) Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70 (3): 1053-1062.
24. Bliss CL, (1939) Toxicity of poisons applied jointly. Ann Appl Biol 26: 585.
25. Greco WR, Bravo G, Parsons JC, (1995) The search for synergy: A critical review from a response surface perspective. Pharmacol Rev 47 (2): 331-385.
26. Webb JL, (1963) Effect of more than one inhibitor. Anonymous Enzyme and Metabolic Inibitors New York Academic Press pp. 66-79 & 487-512.
27. Borel JF, Feurer C, Gubler HU, Stahelin H, (1976) Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions 6 (4): 468-475.
28. Sharpe RJ, Arndt KA, Bauer SI, Maione TE, (1989) Cyclosporine inhibits basic fibroblast growth factor-driven proliferation of human endothelial cells and keratinocytes. Arch Dermatol 125 (10): 1359-1362.
29. Benelli U, Ross JR, Nardi M, Klintworth GK, (1997) Corneal neovascularization induced by xenografts or chemical cautery. inhibition by cyclosporin A. Invest Ophthalmol Vis Sci 38 (2): 274-282.
30. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, et al. (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66 (4): 807-815.
31. Nacev B, Low WK, Huang Z, Su T, Su Z, et al. (2011) A calcineurin-independent mechanism of angiogenesis inhibition by a non-immunosuppressive cyclosporin A analog. J Pharmacol Exp Ther 338 (2): 466.
32. Lamb DC, Kelly DE, Waterman MR, Stromstedt M, Rozman D, et al. (1999) Characteristics of the heterologously expressed human lanosterol 14alpha-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and candida albicans CYP51 with azole antifungal agents. Yeast 15 (9): 755-763.
33. Trosken ER, Adamska M, Arand M, Zarn JA, Patten C, et al. (2006) Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and candida albicans for inhibition by different antifungal azoles. Toxicology 228 (1): 24-32.
34. Xu J, Dang Y, Ren YR, Liu JO, (2010) Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci U S A 107 (10): 4764-4769.
35. Wei S, Nacev BA, Bhat S, Liu JO, (2010) Imapct of absolute stereochemistry on the antiangiogenic and antifungal activities of itraconazole. ACS Med Chem Lett 1 (4): 155.
36. Cruz MC, Goldstein AL, Blankenship JR, Del Poeta M, Davis D, et al. (2002) Calcineurin is essential for survival during membrane stress in candida albicans. EMBO J 21 (4): 546-559.
37. Hartman JL 4th, Garvik B, Hartwell L, (2001) Principles for the buffering of genetic variation. Science 291 (5506): 1001-1004.